系统性红斑狼疮中非免疫介导肾病的综述: putative 危险因素的假设模型
约半数系统性红斑狼疮(SLE)患者被诊断为狼疮肾炎(LN)。SLE患者糖尿病、高血压和肥胖风险增加,这三者在普通人群终末期肾病中合计占>70%。作者假设SLE患者中相当比例且不断增加的肾脏病理可能并非直接与LN相关,而可由糖尿病、高血压和肥胖等非免疫介导因素解释。
要点
- SLE患者中糖尿病、高血压和肥胖常见,可能是肾脏损害的替代原因。
- SLE肾脏病因误分类可能影响临床试验招募、流行病学研究和临床照护。
- 亟需在临床和组织学上区分SLE患者肾病的 discrete 病因。
核心结论
- SLE患者中相当比例且不断增加的肾脏病理可能并非直接与LN相关,而可由糖尿病、高血压和肥胖等非免疫介导因素解释。
- SLE患者肾脏病因误分类可能对临床试验招募、流行病学研究和临床照护产生重要影响。
研究设计与样本
- 综述(Semin Arthritis Rheum),基于文献汇总提出关于SLE中非免疫介导肾病的假设模型,未报告系统检索范围与样本量。
主要发现
- 约半数SLE患者被诊断为LN。
- SLE患者糖尿病、高血压和肥胖风险增加,这三者在普通人群终末期肾病中合计占>70%。
- SLE中非LN相关肾脏病因的频率及其对肾脏病发生和进展的贡献研究不足。
临床怎么用
- 临床应关注SLE患者中高血压、糖尿病和肥胖作为潜在肾脏损害替代原因。
- 建议风湿科、病理科、肾内科和内分泌科协作,在临床和组织学上区分SLE肾病的 discrete 病因。
局限性
- 为假设性综述,未提供系统检索范围、样本量或定量汇总数据。
- SLE中非LN相关肾脏病因的频率及其贡献研究不足,结论需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
About half of patients with systemic lupus erythematosus (SLE) are diagnosed with lupus nephritis (LN). Patients with SLE are also at increased risk for diabetes, hypertension and obesity, which together account for >70% of end-stage renal disease in the general population. The frequencies of non-LN related causes of kidney disease, and their contribution to kidney disease development and progression among patients with SLE have been inadequately studied. We hypothesize that a substantial, and increasing proportion of kidney pathology in patients with SLE might not directly relate to LN but instead might be explained by non-immune mediated factors such as diabetes, hypertension, and obesity. The goal of the manuscript is to draw attention to hypertension, diabetes and obesity as potential alternative causes of kidney damage in patients with SLE. Further, we suggest that misclassification of kidney disease etiology in patients with SLE might have important ramifications for clinical trial recruitment, epidemiologic investigation, and clinical care. Future studies aiming to elucidate and distinguish discrete causes of kidney disease - both clinically and histologically - among patients with SLE are desperately needed as improved understanding of disease mechanisms is paramount to advancing therapeutic discovery. Collaboration among rheumatologists, pathologists, nephrologists, and endocrinologists, and the availability of dedicated research funding, will be critical to the success of such efforts.
引用
- Falasinnu T, O'Shaughnessy MM, Troxell ML, et al. A review of non-immune mediated kidney disease in systemic lupus erythematosus: A hypothetical model of putative risk factors. Semin Arthritis Rheum. 2019. PMID: 31866044. doi:10.1016/j.semarthrit.2019.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。